Ribonucleotide reductase inhibitors are a family of anti-cancer drugs that interfere with the growth of tumor cells by blocking the formation of deoxyribonucleotides (building blocks of DNA).
Examples include:
- motexafin gadolinium.[1]
- hydroxyurea[2]
- fludarabine, cladribine, gemcitabine, tezacitabine, and triapine[3]
- gallium maltolate, gallium nitrate[4]
- Tezacitabine, Tezacitabine[5] A chemotherapy candidate nucleotide analogue that failed in clinical trials due to on-target toxicity (febrile neutropenia).[6]
See also
References
- ↑ Zahedi Avval F, Berndt C, Pramanik A, Holmgren A (January 2009). "Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd)". Biochem. Biophys. Res. Commun. 379 (3): 775–9. doi:10.1016/j.bbrc.2008.12.128. PMID 19121624.
- ↑ Mayhew CN, Phillips JD, Cibull ML, Elford HL, Gallicchio VS (September 2002). "Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea". Antivir. Chem. Chemother. 13 (5): 305–14. doi:10.1177/095632020201300506. PMID 12630679.
- ↑ Tsimberidou AM, Alvarado Y, Giles FJ (August 2002). "Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies". Expert Rev Anticancer Ther. 2 (4): 437–48. doi:10.1586/14737140.2.4.437. PMID 12647987. S2CID 30047759.
- ↑ Bernstein LR (1998). "Mechanisms of therapeutic activity for gallium" (PDF). Pharmacol. Rev. 50 (4): 665–682. PMID 9860806.
- ↑ Bitonti, A. J.; Dumont, J. A.; Bush, T. L.; Cashman, E. A.; Cross-Doersen, D. E.; Wright, P. S.; Matthews, D. P.; McCarthy, J. R.; Kaplan, D. A. (15 March 1994). "Regression of human breast tumor xenografts in response to (E)-2'-deoxy-2'-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase". Cancer Research. 54 (6): 1485–1490. PMID 8137252.
- ↑ "Tezacitabine monohydrate".
External links
- Ribonucleotide reductase inhibitor entry in the public domain NCI Dictionary of Cancer Terms
This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.